Equities Analysts Set Expectations for Surrozen Q3 Earnings

Key Points

• HC Wainwright has increased its Q3 2025 earnings per share forecast for Surrozen to ($1.17), raising the target price to $32.00, while maintaining a "Buy" rating.
• The company recently reported earnings of ($1.14) per share, exceeding expectations, with a significant negative net margin of 274.42% and a negative return on equity of 545.43%.
• Institutional investors own 66.57% of Surrozen, with notable increases in holdings from firms like Geode Capital Management and Stonepine Capital Management.

Surrozen, Inc. (NASDAQ:SRZN - Free Report) - Research analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for shares of Surrozen in a report issued on Monday, August 11th. HC Wainwright analyst M. Caufield now expects that the company will earn ($1.17) per share for the quarter, up from their previous forecast of ($1.21). HC Wainwright currently has a "Buy" rating and a $32.00 target price on the stock. The consensus estimate for Surrozen's current full-year earnings is ($8.49) per share. HC Wainwright also issued estimates for Surrozen's Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($2.83) EPS, FY2026 earnings at ($4.84) EPS, FY2027 earnings at ($5.59) EPS, FY2028 earnings at ($6.46) EPS and FY2029 earnings at ($7.29) EPS.

Surrozen (NASDAQ:SRZN - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.23) by $0.09. Surrozen had a negative return on equity of 545.43% and a negative net margin of 274.42%.The business had revenue of $0.98 million during the quarter.

Surrozen Stock Down 1.8%

SRZN stock traded down $0.20 during trading on Thursday, reaching $10.84. The company's stock had a trading volume of 1,529 shares, compared to its average volume of 19,705. The company has a market capitalization of $92.79 million, a P/E ratio of -0.74 and a beta of 0.60. The company's fifty day moving average is $9.29 and its 200-day moving average is $9.81. Surrozen has a 1 year low of $5.90 and a 1 year high of $18.17.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SRZN. Adage Capital Partners GP L.L.C. bought a new stake in Surrozen in the fourth quarter worth about $928,000. Vivo Capital LLC bought a new stake in Surrozen in the first quarter worth about $3,032,000. Stempoint Capital LP lifted its stake in Surrozen by 91.7% in the fourth quarter. Stempoint Capital LP now owns 350,573 shares of the company's stock worth $5,031,000 after purchasing an additional 167,655 shares during the last quarter. Geode Capital Management LLC lifted its stake in Surrozen by 26.1% in the fourth quarter. Geode Capital Management LLC now owns 22,391 shares of the company's stock worth $321,000 after purchasing an additional 4,630 shares during the last quarter. Finally, Stonepine Capital Management LLC lifted its stake in Surrozen by 24.7% in the fourth quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company's stock worth $1,969,000 after purchasing an additional 27,200 shares during the last quarter. Institutional investors own 66.57% of the company's stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.